BARSTATIN 100
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BARSTATIN 100 (BARSTATIN 100).
HMG-CoA reductase inhibitor; decreases cholesterol synthesis in the liver by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, leading to upregulated LDL receptor expression and enhanced clearance of LDL from the bloodstream.
| Metabolism | Primarily metabolized by CYP3A4 isoenzyme; undergoes extensive first-pass metabolism in the liver. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 30% as metabolites |
| Half-life | Terminal elimination half-life: 3-4 hours; in renal impairment (CrCl <30 mL/min) extended to 8-12 hours; clinical context: supports twice-daily dosing in normal renal function |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.15 L/kg; indicates limited extravascular distribution, primarily confined to plasma volume |
| Bioavailability | Oral: 85%; intravenous: 100% |
| Onset of Action | Oral: 1-2 hours; intravenous: 15-30 minutes |
| Duration of Action | Oral: 8-12 hours; intravenous: 6-8 hours; clinical notes: lipid-lowering effect persists with sustained dosing |
| Molecular Weight | 404.54 Da |
100 mg orally once daily.
| Dosage form | POWDER |
| Renal impairment | GFR 30-59 mL/min: 50 mg once daily; GFR <30 mL/min: 25 mg once daily. |
| Liver impairment | Child-Pugh Class A: no dose adjustment; Child-Pugh Class B: 50 mg once daily; Child-Pugh Class C: contraindicated. |
| Pediatric use | Children 10-17 years: 2 mg/kg/day (max 100 mg/day) orally once daily; Children <10 years: not established. |
| Geriatric use | Start at 50 mg once daily; titrate cautiously based on renal function. |
| 1st trimester | Contraindicated due to potential teratogenicity; statins inhibit HMG-CoA reductase essential for fetal development. Alternate antihyperlipidemic therapy recommended. |
| 2nd trimester | Contraindicated; exposure may interfere with fetal cholesterol synthesis, which is critical for organogenesis and growth. |
| 3rd trimester | Contraindicated; limited safety data, but theoretical risk of fetal toxicity and interference with steroidogenesis. |
Clinical note
Comprehensive clinical and safety monograph for BARSTATIN 100 (BARSTATIN 100).
| Placental transfer | Statins are known to cross the placenta; animal studies show fetal risk. Human data insufficient, but transfer is likely based on molecular weight and lipophilicity. |
| Breastfeeding | Excreted into breast milk in unknown amounts; potential for serious adverse reactions in nursing infants. Discontinue drug or avoid breastfeeding; use alternative agents if lipid-lowering therapy is required. |
■ FDA Black Box Warning
No FDA boxed warning reported.
| Serious Effects |
Active liver diseaseUnexplained persistent elevations of serum transaminasesPregnancyLactationHypersensitivity to barastatin
| Precautions | Risk of myopathy/rhabdomyolysis, especially with concomitant use of strong CYP3A4 inhibitors, cyclosporine, or gemfibrozil, Hepatic enzyme elevations; monitor liver function tests before and during therapy, Avoid in active liver disease or unexplained persistent transaminase elevations, Caution in patients with predisposing factors for renal impairment |
| Food/Dietary | Avoid grapefruit and grapefruit juice during therapy, as they inhibit CYP3A4 and increase statin levels. Limit alcohol intake to reduce risk of liver damage. |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of congenital anomalies, particularly CNS and cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and neonatal hypolipidemia. |
| Fetal Monitoring | Baseline and periodic liver function tests; renal function tests; creatine kinase levels if neuromuscular symptoms; fetal ultrasound for growth assessment if inadvertent exposure; lipid panels to assess efficacy. |
| Fertility Effects | No significant effects on fertility in animal studies. In humans, reduced sperm motility and count reported in males; effects reversible upon discontinuation. |
| Clinical Pearls | BARSTATIN 100 is a high-intensity statin; monitor for muscle pain, tenderness, or weakness, especially in patients on concurrent CYP3A4 inhibitors. Check baseline liver function and CPK; avoid in active liver disease or unexplained transaminase elevations. Consider dose reduction if used with potent CYP3A4 inhibitors (e.g., clarithromycin, itraconazole). |
| Patient Advice | Take BARSTATIN 100 exactly as prescribed, at the same time each day, preferably in the evening. · Do not take with grapefruit or grapefruit juice; avoid large amounts of alcohol. · Report any unexplained muscle pain, tenderness, or weakness to your doctor immediately. · Inform your doctor of all other medications, including over-the-counter drugs and supplements. · Maintain a heart-healthy diet and exercise regimen as advised by your healthcare provider. |